Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Wockhardt Limited
The damage at one of Pfizer’s largest injectables facilities could lead to gains for a few Indian companies, analysts feel. However, regulatory risks, litigation pay-outs and other challenges will slow growth for domestic firms and Indian units of multinationals like Abbott and Pfizer in FY24, says rating agency ICRA as Q1 results begin coming in
Could more Indian firms consider re-aligning their US business amid heightened pricing and compliance pressures that have cast a shadow on the long-term viability of the generics segment? A cross section of experts including a senior executive at McKinsey & Co share their views on what to expect.
Wockhardt expects to save up to $12m through restructuring its US business, eyeing up a potential return to profitability by 2025.
Investments in differentiated and specialty products and collaborations, alongside divestitures, are part of Dr Reddy’s plans as it seeks to move up the rankings in India. Momentum in China, including an alliance with Sunflower Pharma for orphan diseases, is also being keenly watched.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.